Hello
Welcome to mPixl
mPixl is focused on helping doctors fight blood cancer.
What we do
Pioneering vision
mPixl uses the power of magnetic resonance imaging and machine learning to quantify the health status of the bone marrow.
The bone marrow is the spongy tissue inside the bones, where the cells of the immune system are formed.
In myeloma, the disease can be active in multiple places throughout the body, so the most sensitive method of detecting it is by whole-body MRI.
At mPixl, we can automate the analysis and reporting process, so that patients are referred to treatment earlier. The earlier the detection, the better the outcome.
1.
Identify and quantify active disease from whole-body MRIs.
2.
Monitor response to therapy, allowing real-time feedback to the clinical team on disease progression.
3.
Identify patients likely to relapse.
We are currently setting up collaborations to start first-in human clinical trials to fully validate mpixl in the clinical scenario.
Mission Statement
Change the future
To accelerate bone marrow disease diagnosis.
Fist Focus
Myeloma is treatable but not curable.
Myeloma affects multiple places in the body, which is why it is referred to sometimes as ‘multiple’ myeloma.
The NICE Guidelines for myeloma pinpoint MRI as the preferred method to diagnose this disease, and to monitor response to treatmet
Yet, only 27% of hospitals actually use whole-body MRI. Main problems are scanner availability, financial constraints, reporting time, and radiologist training.
Royal College Radiologist Report, 2021
We aim to reduce reporting time, and be less dependent on radiologist training. This is particularly important in cases where the MRI scan seems inconclusive and the patient is either asymptomatic or has a non-secreting form of myeloma.
mPixl method is a add-on method to monitor these patients by taking advantage of the full potential of already available imaging technologies, and combine it with the power of machine learning.
It is a step towards personalized treatment pathway as it will provide a quantitative prognostic method to assess the likelihood of chemotherapy resistance, and to monitor response to treatment, allowing for faster adjustments of treatment dosage/timings.
For whom
mPixl was designed with both patients and clinicians in mind.
For Patients
mPixl was designed to help you get a quicker diagnose, so you can be on top of your disease. You will not need to do anything extra.
For clinicians
mPixl will help you achieve the best care possible, patient by patient by speeding up the analysis process enabling shortening of reporting times.
mPixl is especially useful for myeloma patients that are asymptomatic at diagnosis, or non-secreting patients where it’s hard to quantify response to treatment.
How it works
Reducing the timeline of the process
First step
An MRI scan is taken, as part of the clinical pathway;
Second step
MRI get uploaded to the server; mPixl sends the report back to the clinical team
Third step
The radiology team revises the report, and feeds the information to the remaining clinical team
Fourth step
The patient pathway is adjusted according to report results.
The Team
Passionate about change
Ana Gomes, PhD
Co-Founder and CEO
Ana has been a researcher in the life science sector since 2005, with extensive expertise in preclinical models of disease, and working on MRI applications since 2015.
Stefan Videv, PhD
Co-Founder and CTO
With over 8 years of experience in translating technology research, Stefan areas of expertise include algorithms, machine learning, signal processing, and hardware design.
